← Bio-Techne overview

Bio-Techne vs Sansure Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bio-Techne Corp (TECH)

Q3 2026
▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

  • Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.

    This is the latest and most important step in the buyout that now defines TECH's price.

  • Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.

    It is a new, concrete regulatory clearance that directly supports deal completion.

  • Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.

    It shows the acquirer is financially strong and committed, which supports the deal price.

  • Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.

    It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

August 2026
▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

  • Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.

    This is the latest and most important step in the buyout that now defines TECH's price.

  • Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.

    It is a new, concrete regulatory clearance that directly supports deal completion.

  • Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.

    It shows the acquirer is financially strong and committed, which supports the deal price.

  • Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.

    It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Latest
▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

  • Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.

    This is the latest and most important step in the buyout that now defines TECH's price.

  • Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.

    It is a new, concrete regulatory clearance that directly supports deal completion.

  • Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.

    It shows the acquirer is financially strong and committed, which supports the deal price.

  • Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.

    It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Q2 2026
▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

  • Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.

    This is the single new event that explains the stock's move and future path.

  • Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.

    It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.

  • Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.

    It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

June 2026
▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

  • Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.

    This is the single new event that explains the stock's move and future path.

  • Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.

    It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.

  • Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.

    It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

  • Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.

    This is the single new event that explains the stock's move and future path.

  • Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.

    It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.

  • Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.

    It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

Sansure Biotech Inc (688289.CG)

Q3 2026
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.

August 2026
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.

Latest
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.